CN106166159A - A kind of compound injection anesthetis - Google Patents

A kind of compound injection anesthetis Download PDF

Info

Publication number
CN106166159A
CN106166159A CN201610539604.2A CN201610539604A CN106166159A CN 106166159 A CN106166159 A CN 106166159A CN 201610539604 A CN201610539604 A CN 201610539604A CN 106166159 A CN106166159 A CN 106166159A
Authority
CN
China
Prior art keywords
component
compound injection
anesthetis
injection anesthetis
etomidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610539604.2A
Other languages
Chinese (zh)
Inventor
孙剑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610539604.2A priority Critical patent/CN106166159A/en
Publication of CN106166159A publication Critical patent/CN106166159A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A kind of compound injection anesthetis, comprising: component A:

Description

A kind of compound injection anesthetis
Technical field
The present invention relates to a kind of compound injection anesthetis.
Background technology
Anesthetics is requisite medicine in medical surgery, is generally divided into general anesthetic and local anesthetic, and complete Body anesthetics deeply suppresses cerebral cortex, makes people's mind disappear.Tradition use general anesthetic by ether and fluorochemical, But such medicine storage request is higher, and photodissociation, pyrolysis, poor stability easily occur, and deposits and there is impurity the most at once, impact anesthesia effect Really, Anesthetic safety accident is even resulted in.Therefore in the urgent need to exploitation one for stablize that anesthetis is efficient, have no side effect, nothing Impurity, deposit.
Summary of the invention
It is an object of the invention to provide one and deposit stable, free from admixture produces, use safe efficient, have no side effect Compound injection anesthetis.
The technical scheme is that a kind of compound injection anesthetis, comprising:
Component A:;
In formula: R1 be 2 to 5 by the polynucleation hydrocarbon group of the condensation of 3 to 6 yuan of cyclic condensations；
Component B: sorbitan fatty acid ester；
Component C: etomidate;
Component D: mepivacaine;
Component E:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids.
2, a kind of compound injection anesthetis according to claim 1, is characterized in that: described component A:B:C:D:E matter Amount ratio=2:1:5:30:3.
Use this compound to prepare anesthetics, can avoid producing, store, transport in decompose and produce impurity, impact anesthesia Safety, improves safety in utilization.
Detailed description of the invention
1, a kind of compound injection anesthetis, comprising:
Component A:;
In formula: R1 be 2 to 5 by the polynucleation hydrocarbon group of the condensation of 3 to 6 yuan of cyclic condensations；
Component B: sorbitan fatty acid ester；
Component C: etomidate;
Component D: mepivacaine;
Component E:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids.
Component A:B:C:D:E mass ratio=2:1:5:30:3.

Claims (2)

1. a compound injection anesthetis, comprising:
Component A:;
In formula: R1 be 2 to 5 by the polynucleation hydrocarbon group of the condensation of 3 to 6 yuan of cyclic condensations；
Component B: sorbitan fatty acid ester；
Component C: etomidate;
Component D: mepivacaine;
Component E:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids.
A kind of compound injection anesthetis the most according to claim 1, is characterized in that: described component A:B:C:D:E mass ratio= 2:1:5:30:3.
CN201610539604.2A 2016-07-11 2016-07-11 A kind of compound injection anesthetis Pending CN106166159A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610539604.2A CN106166159A (en) 2016-07-11 2016-07-11 A kind of compound injection anesthetis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610539604.2A CN106166159A (en) 2016-07-11 2016-07-11 A kind of compound injection anesthetis

Publications (1)

Publication Number Publication Date
CN106166159A true CN106166159A (en) 2016-11-30

Family

ID=58064690

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610539604.2A Pending CN106166159A (en) 2016-07-11 2016-07-11 A kind of compound injection anesthetis

Country Status (1)

Country Link
CN (1) CN106166159A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050077497A1 (en) * 2003-10-08 2005-04-14 David Anderson Stabilized uncoated particles of reversed liquid crystalline phase materials
CN101765582A (en) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 Deuterium-labelled ketamine
CN101896205A (en) * 2007-08-27 2010-11-24 惠氏有限责任公司 Use nmda antagonist to be used to obtain the compositions and the method for anesthetic-sparing effect
CN102844022A (en) * 2010-04-21 2012-12-26 帝国制药美国公司 Local anesthetic emulsion compositions and methods of making and using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050077497A1 (en) * 2003-10-08 2005-04-14 David Anderson Stabilized uncoated particles of reversed liquid crystalline phase materials
CN101765582A (en) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 Deuterium-labelled ketamine
CN101896205A (en) * 2007-08-27 2010-11-24 惠氏有限责任公司 Use nmda antagonist to be used to obtain the compositions and the method for anesthetic-sparing effect
CN102844022A (en) * 2010-04-21 2012-12-26 帝国制药美国公司 Local anesthetic emulsion compositions and methods of making and using the same

Similar Documents

Publication Publication Date Title
NZ627274A (en) Anesthetic compounds and related methods of use
Jung et al. Bradycardia during laparoscopic surgery due to high flow rate of CO2 insufflation
Xiang et al. Impact of supraglottic device with assist ventilation under general anesthesia combined with nerve block in uniportal video-assisted thoracoscopic surgery
CN106166159A (en) A kind of compound injection anesthetis
CN106138015A (en) Propofol self-micro-emulsifying composition
Chaudhary et al. Oral premedication with pregabalin and clonidine for hemodynamic stability during laryngoscopy: A comparative study.
CN106176770A (en) A kind of male's period of development injecting narcotic
CN106187850A (en) One can be used as narcotic compound
CN106109468A (en) A kind of women period of development injecting narcotic
CN106565580A (en) Anesthetic stabilizer
CN103271913A (en) Application of Myriberine A in preparing thrombocyte-increasing medicines
CN106038487A (en) Intravenous injection emulsion anesthetic for pregnant women
Küçük et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder: a perspective from anesthesiologists
CN106176746A (en) A kind of child's injecting narcotic
CN106176762A (en) A kind of local anesthesia anesthetis
LI et al. The application of nalmefene in sufentanil and propofol anesthesia for abortion
CN102988380B (en) Application of Houttuynoid B in preparation of medicine for rising white blood cells
CN106220613A (en) The anti-frightened fault additive of a kind of anesthetis
CN103751178B (en) The application of Trigoxyphin K in increased platelets counts medicine
CN102988392B (en) Application of Houttuynoid B in preparation of medicine for rising red blood cells
Amin et al. Controlled Hypotensive Anesthesia in Children Undergoing Nasal Surgery
Gupta et al. Comparative evaluation of caudal fentanyl and clonidine as adjuvant to bupivacaine for post-operative analgesia in pediatric genitourinary and inguinal surgeries
황성미 et al. Cooperation with anesthesiologists for acute airway management in the emergency department-A case report
Zhang et al. The comparison of different inserting time on patients under propofol combined sufentanil anesthesia in gastroscopy
Yingchun et al. The clinical application of monitored anesthesia care in percutaneous dilatational tracheostomy.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161130

WD01 Invention patent application deemed withdrawn after publication